Important Innovations Collection

1st Pfizer/BioNTech COVID Vaccine,  Now Moderna Vaccine                                    Source: Moderna COVID Vaccine Moderna Vaccine is 94.5% Effective, Pfizer More than 90% More hope in the fight against the COVID-19 global pandemic.  Cambridge, MA based biotech Moderna reports tonight that it has a COVID vaccine candidate that is 94.5% effective against the deadly virus .  COVID-19 has infected nearly 55 million people and taken more than 1.3 million lives globally as of today.  Pfizer/Germany's BioNTech Vaccine Moderna has the second highly acclaimed vaccine candidate since Pfizer/BioNTech announced theirs a few days ago.  Pfizer claims their vaccine has a more than 90% effective rate. These vaccines have to be approved by regulatory authorities, but their results look very promising and are giving global medical experts hope of quick turnaround deploy...

Closing in on COVID Vaccines Source:  European Commission President Ursula Von Der Leyen & Council President Charles Michel EU Historic Stimulus Package Researchers at Oxford University in the UK, along with AstraZeneca, have developed a COVID vaccine that is proving to be successful at building immunity against COVID.  Human trials on more than 1000 patients have proven the vaccine effective.  The vaccine has moved into combined Phase 2 and Phase 3 trials - the last stop to prove it works.  AstraZeneca has a $1.2 billion deal with the US to deliver 300 million doses this fall, if the vaccine is approved. Two More Vaccines Meanwhile, at Moderna Pharma in Cambridge, MA, an experimental mRNA vaccine is in human trials and it is proving to be effective. It has produced antibodies in all the patients involved in the trials And, in China biotech Cansino's vaccine is showing positive antibody responses in a Phase 2 trial.  It is entering Phase 3 ...